Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Sell

Wall Street Data Solutions Rating

Buy

A

Natera, Inc. Common Stock (NTRA)

Services-medical Laboratories

https://www.natera.com

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

13011 MCCALLEN PASS, BUILDING A SUITE 100
AUSTIN, TX

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/02/2015

Market Cap

15,232,551,960

Shares Outstanding

120,150,000

Weighted SO

120,151,688

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

EXAS --.--%

CDNA --.--%

ILMN --.--%

TWST --.--%

PSNL --.--%

GH --.--%

CSTL --.--%

QGEN --.--%

NEO --.--%

Beta

1.4800

Last Div

0.0000

Range

36.9-123.86

Chg

0.9100

Avg Vol

1339420

Mkt Cap

15232551960

Exch

NASDAQ

Country

US

Phone

650 249 9090

DCF Diff

7.5182

DCF

36.2218

Div Yield

0.0000

P/S

11.1963

EV Multiple

-53.2450

P/FV

18.0875

Div Yield %

0.0000

P/E

-51.7950

PEG

-1.3593

Payout

0.0000

Current Ratio

4.1383

Quick Ratio

4.0081

Cash Ratio

2.5329

DSO

90.1260

DIO

23.8256

Op Cycle

113.9515

DPO

19.2418

CCC

94.7097

Gross Margin

0.5385

Op Margin

-0.2306

Pretax Margin

-0.2135

Net Margin

-0.2147

Eff Tax Rate

-0.0059

ROA

-0.1926

ROE

-0.3674

ROCE

-0.2609

NI/EBT

1.0059

EBT/EBIT

0.9257

EBIT/Rev

-0.2306

Debt Ratio

0.2481

D/E

0.4499

LT Debt/Cap

0.2532

Total Debt/Cap

0.3103

Int Coverage

-49.0439

CF/Debt

-0.1506

Equity Multi

1.8135

Rec Turnover

4.0499

Pay Turnover

18.9691

Inv Turnover

15.3197

FA Turnover

7.3200

Asset Turnover

0.8968

OCF/Share

-0.4614

FCF/Share

-0.8735

Cash/Share

7.2208

OCF/Sales

-0.0417

FCF/OCF

1.8930

CF Coverage

-0.1506

ST Coverage

-0.6111

CapEx Coverage

-1.1198

Div&CapEx Cov

-1.1198

P/BV

18.0875

P/B

18.0875

P/S

11.1963

P/E

-51.7950

P/FCF

-141.9424

P/OCF

-266.9050

P/CF

-266.9050

PEG

-1.3593

P/S

11.1963

EV Multiple

-53.2450

P/FV

18.0875

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Feb 26, 01:30 Liquid Biopsy Market Worth US$11.3 billion at a robust CAGR of 11.9% | MarketsandMarkets™. GlobeNewswire Inc. Sep 13, 00:30 Liquid Biopsy Market to Reach $ 32.54 Billion, Globally, by 2033 at 11.61% CAGR: The Brainy Insights Benzinga Jan 17, 14:00 Expert Ratings For Natera Benzinga Dec 29, 09:20 Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday Benzinga Dec 29, 07:00 The Analyst Landscape: 8 Takes On Natera MarketWatch Dec 28, 07:46 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky MarketWatch Dec 28, 06:34 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky Benzinga Dec 12, 11:00 The Latest Analyst Ratings for Natera

Revenue Product Segmentation